Discover
NAUT
Nautilus Biotechnology, Inc.
1.84
2 x 1.43
2 x 2.40
bid
ask
-
0.03
1.60%
2 @ 04:00 PM
1.80 -0.04 (2.17%)
| Ytd | -5.64% | |
| 1y | 152.05% |
1.83
day range
2.00
0.62
52 week range
4.31
| Open | 1.88 | Prev Close | 1.87 | Low | 1.83 | High | 2.00 | Mkt Cap | 233.83M |
| Vol | 2.35M | Avg Vol | 558.90K | EPS | -0.46 | P/E | N/A | Forward P/E | -2.32 |
| Beta | 1.04 | Short Ratio | 9.26 | Inst. Own | 50.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 2.50 | 200-d Avg | 2.15 | 1yr Est | 3.44 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-29 | 2024-09 | -0.17 | -0.13 | 0.04 | 23.53% |
| 2024-07-30 | 2024-06 | -0.16 | -0.14 | 0.02 | 12.50% |
| 2024-07-30 | 2024-06 | -0.16 | N/A | N/A | N/A |
| 2024-04-30 | 2024-03 | -0.16 | -0.15 | 0.01 | 6.25% |
| 2024-04-30 | 2024-03 | -0.16 | N/A | N/A | N/A |
| 2024-02-28 | 2023-12 | -0.16 | -0.14 | 0.02 | 12.50% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-05 | Goldman Sachs | Downgrade | Neutral | Sell |
| 2024-06-27 | Guggenheim | Upgrade | Buy | |
| 2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2022-08-03 | Morgan Stanley | Upgrade | Equal-Weight | |
| 2022-08-03 | Goldman Sachs | Upgrade | Neutral | |
| 2022-07-14 | Goldman Sachs | Upgrade | Neutral |
Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-22 | GODWIN MARY E | Officer | 0.00 | Conversion of Exercise of derivative security |
| 2024-03-10 | PATEL SUJAL M | Chief Executive Officer | 17.16M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Ah Capital Management, L.L.C. | 17.65M | 30.36M | 14.06% |
| 2024-09-29 | Perceptive Advisors Llc | 12.59M | 21.66M | 10.03% |
| 2024-09-29 | Cercano Management Llc | 7.17M | 12.34M | 5.71% |
| 2024-09-29 | Madrona Venture Group, LLC | 6.02M | 10.36M | 4.79% |
| 2024-09-29 | Blackrock Inc. | 3.57M | 6.13M | 2.84% |
| 2024-09-29 | Vanguard Group Inc | 2.77M | 4.76M | 2.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.75M | 3.00M | 1.39% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.20M | 2.07M | 0.96% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 670.13K | 1.15M | 0.53% |
| 2024-10-30 | iShares Biotechnology ETF | 519.94K | 894.30K | 0.41% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 491.43K | 845.26K | 0.39% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 433.69K | 745.94K | 0.35% |